XPro1595 may promote myelin restoration, new mouse study finds
INmune Bio‘s experimental therapy XPro1595 may promote myelin restoration through the activation of two types of nervous system support…
Articles by Lindsey Shapiro, PhD
Tysabri best of 6 DMTs to prevent relapses, worse disability in MS
Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in…
Research supports inclusion of optic nerve in McDonald criteria for MS
Adding optic nerve damage — reflected by a thinning of the nerve layer in the eye’s retina — to the…
Sexual dysfunction could be an issue for 61% of women with MS
Women with multiple sclerosis (MS) are three times more likely to face problems with sexual intimacy than are their…
Myelin may promote nerve cell damage in early immune attacks
Nerve cells coated with myelin — the fatty substance that’s lost in multiple sclerosis (MS) — may be…
AI algorithms may predict cognitive decline in MS over coming year
Researchers have developed computer algorithms that may be able to predict certain aspects of cognitive change in multiple sclerosis…
Diet rich in plant products linked to fewer symptoms in MS
Diet was found to significantly influence the severity of multiple sclerosis (MS) symptoms among patients living in Denmark in…
Regular vaccinations for most MS patients recommended by experts
People with multiple sclerosis (MS) should generally follow a regular vaccination schedule similar to their healthy peers, with certain…
Ocrevus best to prevent MS relapses after stopping Tysabri: Study
Ocrevus (ocrelizumab) — given by infusion — may work better than certain oral treatments to prevent relapses and disability…
Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab
Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive…
Depression not a causal risk factor for disability progression: Study
Physical disability, not whether patients are depressed, when they’re diagnosed with multiple sclerosis significantly influences their future disability progression,…
2nd generation CD40L blocker safely reduces new lesions in Phase 2 trial
Frexalimab, an experimental anti-CD40L antibody therapy from Sanofi, significantly reduced the number of new brain lesions with active inflammation…
Clene wins grant to develop CNM-Au8 for progressive MS
The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for…
Experimental MS therapy vidofludimus calcium triggers Nurr1 protein
Vidofludimus calcium (IMU-838), an investigational multiple sclerosis (MS) therapy with promising results in clinical trials, may exert neuroprotective…
Pro-inflammatory diet linked to relapses after 1st MS attack: Study
A more pro-inflammatory diet is associated with a higher risk of relapses and more inflammatory brain lesions for multiple…
Surgery found successful for some MS patients with facial pain
Surgical procedures to treat trigeminal neuralgia — a type of nerve damage that causes facial pain — may be…
Home-based walking program may boost cognition in MS: Pilot study
A four-month home-based aerobic walking program was feasible and may help improve cognitive function for multiple sclerosis (MS) patients,…
Tysabri found to be safe and effective in real-world Danish study
Tysabri (natalizumab) is generally safe and effectively lowers disease activity in people with multiple sclerosis (MS), according to…
Antibody clumps in blood could drive nerve cell death in MS
Clusters of immunoglobulin G (IgG) antibodies in the blood of multiple sclerosis (MS) patients appear to contribute to the nerve…
AAN 2023: Tolebrutinib safely lowers relapse rates over 2.5 years
About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people…
Greater psychological resilience tied to better outcomes in MS: Study
Multiple sclerosis (MS) patients with greater psychological resilience — a better ability to cope with and recover quickly from…
Immune regulation treatment for MS found safe in 1st human study
OCH, a molecule designed to have beneficial effects on immune regulation in multiple sclerosis (MS), led to increases in…
OCS-05 neuroprotective therapy for MS shows good safety profile
OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of…
Sativex eases MS spasticity and related symptoms in real-life study
Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related…
Bacterial toxin epsilon in gut may be environmental driver of MS
A bacterial toxin in the gut — specifically, the epsilon toxin produced by Clostridium perfringens bacteria in the intestinal tract —…
Orelabrutinib reduces brain lesions in RRMS by 90% in Phase 2 trial
Treatment with InnoCare Pharma’s orelabrutinib — an experimental inhibitor of the Bruton’s tyrosine kinase (BTK) enzyme — led to…
Icobrain MS, an AI tool for assessing MRI scans, being tested in UK
An upcoming study will investigate how well icobrain MS, an artificial intelligence (AI)-based technology, can interpret MRI data from people with…
Study may help explain protective effects of pregnancy in MS
A new study of women with multiple sclerosis (MS) who had previously given birth may have identified one of…
ACTRIMS 2023: GA Depot found to ease MS disability in Phase 3 trial
GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new…
ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’
New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeutics’ novel oral treatment candidate for…